Am. J. Respir. Crit. Care Med., Volume 158, Number 5, November 1998, 1593-1599

High Expression of Neutral Endopeptidase in Idiopathic Diffuse Hyperplasia of Pulmonary Neuroendocrine Cells

ANDREA J. COHEN, TALMADGE E. KING Jr., LAURA B. GILMAN, CATHERINE MAGILL-SOLC, and YORK E. MILLER

Division of Pulmonary Sciences and Critical Care Medicine and the Denver Veterans Administration Medical Center, University of Colorado Health Sciences Center, Denver, Colorado; Department of Medicine, National Jewish Center for Immunology and Respiratory Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco; and Arris Pharmaceuticals, South San Francisco, California

Idiopathic diffuse hyperplasia of pulmonary neuroendocrine cells (IDHPNC) is a clinicopathological entity characterized by a diffuse hyperplasia of neuroendocrine cells involving distal bronchi and bronchioles. The pathogenesis of this syndrome remains unknown. The hyperplastic neuroendocrine (NE) cells contain multiple neuropeptides, including the bombesinlike peptides (BLP), which are likely important in the pathogenesis of the disorder by stimulating proliferation of fibroblasts in a paracrine fashion and the NE cells themselves in an autocrine manner. Neutral endopeptidase (NEP) is a cell-surface enzyme that hydrolyzes BLP and other bioactive peptides. Low or undetectable NEP is present in many primary lung cancers and cell lines. Low NEP expression could increase neuropeptide-induced autocrine effects by increasing local levels of neuropeptides. We hypothesized that IDHPNC was associated with low or absent NEP expression. NEP expression was assayed in patients with IDHPNC (n = 3) and was compared with expression in patients with idiopathic pulmonary fibrosis (n = 5), hypersensitivity pneumonitis (n = 5), and normal lung (n = 4) using immunohistochemistry, ELISA, activity assay, and Western blot analysis. By these assays, NEP expression was highest in lungs affected by IDHPNC. NEP mRNA, as assessed in IDHPNC lung tissue by RT-PCR, was the expected size and free of mutation between bp 238-2437. Therefore, IDHPNC is unlikely to be the result of a defect in NEP expression. The apparent increase in NEP expression in lung tissue from patients with IDHPNC may reflect a compensatory increase that partly counteracts abundant neuropeptides, including BLP, present in this disorder.

This article has been cited by other articles:

				M.-C. Aubry, C. F. Thomas Jr, J. R. Jett, S. J. Swensen, and J. L. Myers Significance of Multiple Carcinoid Tumors and Tumorlets in Surgical Lung Specimens: Analysis of 28 Patients Chest, June 1, 2007; 131(6): 1635 - 1643. [Abstract] [Full Text] [PDF]

				G. Sansoe, M. Aragno, R. Mastrocola, J. C. Cutrin, S. Silvano, G. Mengozzi, A. Smedile, F. Rosina, O. Danni, and M. Rizzetto Overexpression of kidney neutral endopeptidase (EC 3.4.24.11) and renal function in experimental cirrhosis Am J Physiol Renal Physiol, June 1, 2006; 290(6): F1337 - F1343. [Abstract] [Full Text] [PDF]

				E. C. Johney, J. Pfannschmidt, R. J. Rieker, P. A. Schnabel, G. Mechtersheimer, and H. Dienemann Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia and a typical carcinoid tumor J. Thorac. Cardiovasc. Surg., May 1, 2006; 131(5): 1207 - 1208. [Full Text] [PDF]

				A. J. Cohen and Y. E. Miller Notice to subscribers and contributors Am. J. Respir. Cell Mol. Biol., July 1, 1999; 21(1): 1 - 1. [Full Text] [PDF]

				A. J. COHEN, W. A. FRANKLIN, C. MAGILL, J. SORENSON, and Y. E. MILLER Low Neutral Endopeptidase Levels in Bronchoalveolar Lavage Fluid of Lung Cancer Patients Am. J. Respir. Crit. Care Med., March 1, 1999; 159(3): 907 - 910. [Abstract] [Full Text]